title: EBV-Directed T Cell Therapeutics for EBV-Associated Lymphomas.
abstract: Epstein Barr virus (EBV) is a human gamma herpes virus that establishes latency in B cells after primary infection. EBV generally only causes a mild, self-limiting viral illness but is also associated with several malignancies including posttransplantation lymphoproliferative disorder in the immunosuppressed host as well as Hodgkin and non-Hodgkin lymphoma in the immune competent host. The expression of EBV antigens by lymphoma has important applications as targets for adoptive T cell therapy. However, as many lymphomas only express subdominant EBV antigens that are less immunogenic, novel strategies are needed to manufacture EBV-specific T cell products specific for Latent Membrane Protein 1 (LMP1) and LMP2, which are expressed in lymphomas with type II and III latency. While several techniques for manufacturing EBV-CTLs are described in the literature, this chapter focuses on one method for generating Good Manufacturing Practice (GMP)-compliant EBV-specific T cell products that are enriched with LMP1 and LMP2.
authors.affiliation: Department of Hematology/Oncology, Children's National Medical Center, 111 Michigan Ave., Washington, DC, 20010, USA. lmclaugh@childrensnational.org.|The George Washington University, Washington, DC, USA. lmclaugh@childrensnational.org.
authors.forename: Lauren P
authors.initials: LP
authors.lastname: McLaughlin
authors.affiliation: Texas Children's Cancer Center, Texas Children's Hospital, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Stephen
authors.initials: S
authors.lastname: Gottschalk
authors.affiliation: Center for Cell and Gene Therapy, Texas Children's Hospital, Houston Methodist Hospital,, Baylor College of Medicine, Houston, TX, USA.
authors.forename: Cliona M
authors.initials: CM
authors.lastname: Rooney
authors.affiliation: The George Washington University, Washington, DC, USA.|Center for Cancer and Immunology Research, Children's National Medical Center, Washington, DC, USA.
authors.forename: Catherine M
authors.initials: CM
authors.lastname: Bollard
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000956:Antigens, Viral / Q000276:immunology; D002460:Cell Line; D018984:Epitopes, T-Lymphocyte / Q000276:immunology; D020031:Epstein-Barr Virus Infections / Q000150:complications / Q000276:immunology* / Q000821:virology*; D005822:Genetic Vectors / Q000235:genetics; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods; D008223:Lymphoma / Q000209:etiology* / Q000628:therapy*; D016176:T-Lymphocyte Subsets / Q000276:immunology* / Q000378:metabolism; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology / Q000378:metabolism; D014161:Transduction, Genetic; D014763:Viral Matrix Proteins / Q000235:genetics / Q000276:immunology; D014764:Viral Proteins / Q000276:immunology
chemical_list: D000956:Antigens, Viral; C037662:EBV-associated membrane antigen, Epstein-Barr virus; D018984:Epitopes, T-Lymphocyte; D014763:Viral Matrix Proteins; D014764:Viral Proteins
keywords: Adoptive T cell therapy; Epstein Barr virus; Good manufacturing practice; Lymphoma